Skip to main content

Table 1 Baseline characteristics of patients on opioid agonist therapy in Norway

From: Dispensations of benzodiazepines, z-hypnotics, and gabapentinoids to patients receiving opioid agonist therapy; a prospective cohort study in Norway from 2013 to 2017

Baseline characteristics20132014201520162017
No.%No.%No.%No.%No.%
Patients7709 7914 7958 7804 7709 
Deaths165 151 138 114 124 
Patients, excl. deaths7544 7763 7820 7690 7585 
Age
 - ≤ 2521131852171213521202
 - 26-35159021157020155120140318133318
 - 36-45272436273035260533250833329232
 - 46-55228330244932254433254033254834
 - ≥ 56736108291194912110414119216
Mean (SD)43 (10)44 (10)44 (10)44 (10)45 (10)
Gender
 Men522169539069543069535470524569
 Women232331237331239031233630234031
OAT opioidsa
 Methadone, included levomethadone340645326442321641306640298139
 Buprenorphineb413855449958460459462460460461
Potentially addictive drugs
 Dispensed a benzodiazepine and z-hypnoticc374750380949371447375849376250
 Dispensed a gabapentinoid7089662971797621084511
  1. NorPD Norwegian Prescription Database, OAT Opioid agonist therapy, SD Standard deviation
  2. aThe last type of dispensed OAT opioid per year
  3. bInclude buprenorphine-naloxone
  4. cZ-hypnotic includes zolpiclone and zolpidem